Stevenage Bioscience Catalyst one of six new life science opportunity zones in UK
Nadhim Zahawi MP has announced that Stevenage Bioscience Catalyst (SBC) has been successful in its application to become a Life Science Opportunity Zone. The assessment panel consisted of senior industry life science experts and senior government officials. In a...
Stevenage Bioscience Catalyst strengthens Board
Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board. Clare Terlouw, Head of Corporate Development at Syncona Investment Management Limited and Jon Green, Chair of One Nucleus, will be joining the SBC...Stevenage Bioscience Catalysts tenants, Ossianix sign agreement with Novo Nordisk
PHILADELPHIA, PA, USA: Ossianix, Inc. today announced a research collaboration and option agreement with Novo Nordisk to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier (BBB) to the brain. Under the terms of...Dr Sally Ann Forsyth new CEO at Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, is pleased to announce that Dr Sally Ann Forsyth is to join as CEO in March 2018. Dr Forsyth, who joins from Norwich Research Park, has driven the development...
